This cluster is non-informative. The insider sales are tiny relative to Vertex's $134B market cap and likely reflect routine diversification. Monitor upcoming quarterly earnings for any fundamental surprises; the insider activity alone provides no actionable signal.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 7 $522.25entry
- T+1 · 4mo ago −4.56%α −4.25% · $498.43
- T+5 · 4mo ago −8.80%α −9.35% · $476.31
- T+20 · 4mo ago −8.34%α −11.50% · $478.71
- T+60 · 7w ago +0.11%α −1.89% · $522.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two VRTX C-suite executives (CMO and Chief Legal Officer) sold a combined ~$704K in open-market sales over a one-week window. At a $134B market cap, this is ~0.0005%, a trivial amount that is non-informative, likely driven by personal liquidity or tax planning. No insider purchases were reported.
Key Financial Metrics
Key Facts
- EVP and Chief Legal Officer Liu Joy sold 828 shares at $502.71 on 2026-07-01, total $416,243.88
- EVP and CMO Bozic Carmen sold 596 shares at $482.50 on 2026-06-26, total ~$288K
- Total cluster value ~$704K, representing ~0.0005% of Vertex's $134B market cap
- No insider buying in the cluster; net direction is exclusively selling
- Both sellers are C-suite officers but the dollar amounts are immaterial relative to company size
- No 10b5-1 plan data available, but the low frequency and small size are consistent with routine liquidity trades
Financial Impact
Total insider selling of ~$704K, less than 0.001% of market cap. Negligible economic impact.
Risk Factors
- Insiders are selling but at trivial levels, no material risk signal from this activity
- No compensatory insider buying to suggest confidence in near-term outlook
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VRTX-1783409590287 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers